What is Recombinant Antibody?
Recombinant antibodies are antibody fragments generated in vitro through the use of synthetic genes. It brings many advantages, such as high specificity and low immunogenicity levels.
Why is recombinant antibody expression important?
Recombinant antibody expression is the key element in the development of any antibody-derived drugs. It’s required in the process of Antibody Generation and Antibody Optimization. (Fig.1) Recombinant antibody transient expression allows the researchers to predict, screen, and confirm the safety and efficacy of a target antibody in high throughput methods.
Antibody-drug Development Process
The development of antibody drugs involves several stages prior to clinical trials. 1. Target identification To identify a potential target for the antibody, such as a specific protein that is associated with a disease. 2. Antibody generation The identified target will be used as antigens to initiate an immune response in host animals. Then, the generated antibodies will be screened to find the ideal antibody candidate that has strongest binding activity and specificity. 3. Antibody optimization Antibody candidate is modified and further optimize in this stage to improve its effectiveness and affinity. In some cases, antibody humanization step is required. 4. Preclinical studies Safey and efficacy are assessed in animal studies to decide if it can procced to clinical trials.
Fig.1 Antibody-drug Development Process
Antibody Therapeutics, Volume 6, Issue 1, January 2023, Pages 13-29
Challenges along the development process
One of the major challenges associated with the process of antibody drug development is the expression of recombinant antibodies. This is a critical step to create highly specific and effective antibodies that can target disease-causing proteins.
However, this process can be complex and time-consuming, requiring specialized expertise and equipment. Many companies opt to outsource the production of recombinant antibodies to multiple CROs, which can cause difficulties in terms of coordination and quality control. Alternatively, some companies choose to invest in developing in-house capabilities for recombinant antibody expression, which can be expensive and low efficient.
One-Stop Solution of Recombinant Antibody Expression
To overcome this challenge, Bon Opus provides a one-stop solution from hybridoma sequencing, gene synthesis, transient or stable cell line expression, purification, to characterization and scale up to gram level. Our goal is to simplify the process and accelerate the development of novel antibody therapeutics.
We are experts in recombinant technology. In these past 2 years, we have successfully completed over 2000 projects with top-tier biotech and pharmaceutical companies. Moreover, with the new technology, we are now able to offer the best mAb Package in the market!
All-inclusive service for just $385
2 weeks production plus shipping
Guaranteed 200 μg purified mAb
QC report (>95% purity by SEC-HPLC, endotoxin level <1EU/mg)
No delivery, no charge